News Conference News ESC 2025 WHF Stresses the Importance of Polypills in Global Fight Against CVD Yael L. Maxwell September 09, 2025
News Conference News ESC 2024 Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events Michael O'Riordan September 01, 2024
News Conference News ESC 2023 New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground Caitlin E. Cox August 30, 2023
News Conference News ESC 2022 CV Care Around Noncardiac Surgery: New ESC Guidelines Michael O'Riordan September 07, 2022
News Conference News ESC 2022 Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE Michael O'Riordan August 31, 2022
News Conference News ESC 2021 New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy Michael O'Riordan September 03, 2021
News Conference News ESC 2021 No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER Michael O'Riordan September 02, 2021
News Conference News ESC 2021 Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention Michael O'Riordan August 31, 2021
News Conference News ESC 2021 IAMI: Influenza Vaccine Beneficial for Post-MI Patients Michael O'Riordan August 30, 2021
News Conference News ESC 2018 ASCEND: Aspirin Doesn’t Look Good for Primary CV Prevention in Diabetic Patients Todd Neale August 26, 2018
News Conference News ESC 2017 Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed Michael O'Riordan August 29, 2017
News Conference News ESC 2017 CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events Michael O'Riordan August 27, 2017
News Conference News ESC 2016 Optimal Approach for BP Lowering Debated Amid New J-Curve Signals in Stable CAD Todd Neale September 09, 2016
News Conference News ESC 2016 Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER Michael O'Riordan August 30, 2016